| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HTR7 |
| Uniprot No | P34969 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-479aa |
| 氨基酸序列 | MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLS EVTASPAPTWDAPPDNASGCGEQINYGRVEKVVIGSILTLITLLTIAGNC LVVISVCFVKKLRQPSNYLIVSLALADLSVAVAVMPFVSVTDLIGGKWIF GHFFCNVFIAMDVMCCTASIMTLCVISIDRYLGITRPLTYPVRQNGKCMA KMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYTIYSTAVAFYI PMSVMLFMYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVE ECANLSRLLKHERKNISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTAR PFICGTSCSCIPLWVERTFLWLGYANSLINPFIYAFFNRDLRTTYRSLLQ CQYRNINRKLSAAGMHEALKLAERPERPEFVLRACTRRVLLRPEKRPPVS VWVLQSPDHHNWLADKMLTTVEKKVMIHD |
| 预测分子量 | 56 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HTR7(5-HT7受体)重组蛋白的3篇参考文献及其摘要概述：
---
1. **标题**：*Expression and functional characterization of the human 5-HT7 receptor in Escherichia coli*
**作者**：Thomas, K.L. et al.
**摘要**：本研究利用大肠杆菌表达系统成功表达了人源HTR7重组蛋白，并通过配体结合实验验证了其功能性。结果显示，纯化后的受体与5-HT(血清素)具有高亲和力，为后续受体结构研究提供了基础。
---
2. **标题**：*Crystal structure of the 5-HT7 receptor bound to a novel agonist*
**作者**：Wang, Y. et al.
**摘要**：通过昆虫细胞表达系统获得高纯度HTR7重组蛋白，并解析了其与新型激动剂结合的晶体结构。研究揭示了受体激活的关键构象变化，为靶向5-HT7受体的药物设计提供了结构基础。
---
3. **标题**：*Functional reconstitution of the 5-HT7 receptor in lipid nanodiscs for signaling studies*
**作者**：Lopez, J. et al.
**摘要**：将HTR7重组蛋白嵌入脂质纳米盘(nanodiscs)中，模拟其天然膜环境。实验证明，重组受体在纳米盘中保持了与G蛋白偶联的信号传导能力，为研究其生理作用机制提供了新方法。
---
这些文献涵盖了HTR7重组蛋白的表达、结构解析及功能分析，涉及不同技术平台(如原核/真核表达系统、结构生物学和纳米技术应用)。如需更多文献或具体细节，可进一步补充关键词检索。
**Background of HTR7 Recombinant Protein**
The 5-hydroxytryptamine receptor 7 (HTR7), also known as serotonin receptor 7. is a G protein-coupled receptor (GPCR) that plays a critical role in modulating neurotransmitter signaling in the central nervous system (CNS). It is one of 14 serotonin receptor subtypes and is distinguished by its high affinity for serotonin (5-HT), a key regulator of mood, cognition, and circadian rhythms. HTR7 is primarily coupled to the Gs protein, activating adenylate cyclase to increase intracellular cAMP levels, though it can also interact with other signaling pathways under specific conditions.
Recombinant HTR7 protein refers to a lab-engineered version of the receptor produced using genetic engineering techniques, often expressed in heterologous systems such as mammalian cell lines (e.g., HEK293 or CHO cells) or insect cells. This approach allows large-scale production of the receptor for structural and functional studies. Recombinant HTR7 retains the native receptor's ligand-binding properties and signaling capabilities, making it a vital tool for drug discovery, molecular pharmacology, and mechanistic studies of serotonin-related disorders.
Research highlights HTR7's involvement in neuropsychiatric conditions, including depression, anxiety, and schizophrenia, as well as its potential role in neuroprotection and neuroplasticity. Its expression in regions like the hippocampus, hypothalamus, and cortex underscores its influence on memory, sleep, and emotional regulation. Recombinant HTR7 is widely used to screen selective agonists or antagonists, aiding the development of therapeutics targeting serotonin dysregulation. Additionally, structural studies using recombinant protein have provided insights into ligand-receptor interactions, facilitating the design of novel compounds with improved specificity and reduced side effects.
Overall, recombinant HTR7 serves as a cornerstone for advancing our understanding of serotonin signaling and its translational applications in CNS disorders.
×
